Abstract 38P
Background
Most preclinical cancer treatment studies focus on the investigation on monolayer cancer cells. However, there are significant differences in cell characteristics between monolayer cells and solid tumors, thus limiting the potential efficacy of in vitro Photodynamic Therapy (PDT) studies. Hence, PDT studies on 3D spheroids might provide insights in hormonal microenvironment. This study aims to elucidate the efficacy of hexyl-aminolaevulinic acid (H-ALA) mediated PDT on 3D spheroids in hormonal simulated microenvironment.
Methods
MCF7 3D spheroids were cultured by liquid overlay agarose-based technique in the hormonal conditions with estrogen (E2), progesterone (P), and estrogen with progesterone (E2+P). The protoporphyrin IX (PpIX) generated from H-ALA and reactive oxygen species (ROS) were measured and quantified by confocal microscopy and flow cytometry respectively. The hormonal modulated phototoxicity of H-ALA-PDT and estrogen receptor alpha (ERα) expression was determined by MTT assay and flow cytometry respectively.
Results
Compared to H-ALA only, the PpIX generated distributed on the rim of spheroids at short (4h) incubation and, further more diffused into core regions at prolonged (8h) incubation with E2+P. At 50μM and 4J/cm2, the phototoxicity of H-ALA-PDT increased 10% with E2+P. No significant difference of ERα expression with or without hormones, whereas the 1.5- to 2-fold increase of ROS levels at LD50 in all hormonal conditions suggesting the hormonal modulated phototoxicity of H-ALA-PDT might trigger hypoxia but not ERα expression.
Conclusions
This study evidenced that H-ALA-PDT efficacy on MCF7 3D spheroids was enhanced in the hormonal simulated microenvironment. The biomechanism of hormones on PDT efficacy are deserved to be delineated.
Clinical trial identification
Editorial acknowledgement
H-ALA was kindly provided by Photocure ASA.
Legal entity responsible for the study
The authors.
Funding
Research Grants Council (RGC) of the Hong Kong Special Administrative Region, China. This study was supported by a grant from the Research Grants Council (RGC) of the Hong Kong Special Administrative Region, China (Project no.: UGC/FDS17/M06/19).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
28P - Development 68Ga trastuzumab Fab and bioevaluation by PET imaging in HER2/neu-expressing breast cancer patients
Presenter: Yogesh Rathore
Session: Poster viewing 01
29P - Targeting CXCR4 promotes antitumor immunity through TOX-mediated CD8+ T cell activation
Presenter: Canhui Cao
Session: Poster viewing 01
30P - Investigation of KRAS G12C inhibitor JAB-21822 as a single agent and in combination with SHP2 inhibitor JAB-3312 in preclinical cancer models
Presenter: Peng Wang
Session: Poster viewing 01
31P - Photothermal responsive, nucleolin-targeted bimetallic nano-vehicle delivered the combinational therapeutics for improved pancreatic cancer treatment
Presenter: Kandasamy Saravanakumar
Session: Poster viewing 01
32P - Tumor growth inhibition effect of PLAG by regulation of neutrophil infiltration in ICI insensitivity B16F10 melanoma
Presenter: Guen Tae Kim
Session: Poster viewing 01
33P - Establishment of personalized therapeutic for salivary gland cancers based on patients-derived salivary tumoroid model
Presenter: Yoonjin Roh
Session: Poster viewing 01
34P - Association of ACRBP gene polymorphism (+26A/G) to liver cancer and diabetes leads to novel biomarker discovery
Presenter: Md Shariful Islam
Session: Poster viewing 01
35P - Exploring plerixafor as a vector molecule in nuclear medicine for targeting CXCR4 receptor overexpression in vivo
Presenter: Tamanna Lakhanpal
Session: Poster viewing 01
36P - Preclinical evaluation of novel MCL-1 degrader in in vitro and in vivo cancer models
Presenter: Piotr Kowalczyk
Session: Poster viewing 01
37P - Development of splice switching antisense oligonucleotides targeting midkine
Presenter: Graham Robertson
Session: Poster viewing 01